TerminatedPhase 2

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Stopped: Terminated by sponsor

United States, Germany8 participantsStarted 2010-03

Plain-language summary

This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with moderate persistent asthma Exclusion Criteria: * Smokers * Any significant disease or illness, other than asthma Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Change in Forced Expiratory Volume in one second (FEV1) as measured by Spirometry

Timeframe: 28 days

Trial details

NCT IDNCT01103037

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-09

View on ClinicalTrials.gov More Asthma trials